NUTLEY, N.J. & MORRISVILLE, N.C.--(BUSINESS WIRE)--Virtually all patients (98 percent) who received the investigational integrase inhibitor raltegravir, along with FUZEON® (enfuvirtide) and an active boosted protease inhibitor (darunavir), achieved undetectable levels of HIV (less than 400 copies/mL of blood), according to new interim 16-week clinical data presented this week at the 14th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Los Angeles. Such a high response rate has never been seen in patients who have developed resistance to at least one agent in each of the first three classes of antiretrovirals.
